# Thymosin Alpha-1 Research: Mechanism, Trials, and the Honest Evidence Map > Thymosin Alpha-1 research mapped to source — the TLR2/TLR9 dendritic-cell mechanism, the hepatitis and COVID-19 signals, and the null phase-3 sepsis trial, each cited. Each finding logged to its study, the strong signals and the null one held in the same light. ## Before the details Thymosin Alpha-1 research spans biochemistry, immunology, and four decades of clinical trials, so here is the map before the territory. The peptide was isolated and sequenced in 1977. We understand fairly well *how* it works: it nudges the immune system's sentinel cells to mature and present threats, which sharpens the T-cell response, while a second arm keeps that response from running away. The clinical record is broad but uneven. It is strongest in long-term hepatitis B, mixed in COVID-19, and — importantly — negative in the single largest sepsis trial. Below, each claim is tied to a numbered study you can check on [the references page](/references). Where the evidence is thin or conflicting, this page says so rather than smoothing it over. Doses, when they appear, are reported only as what was studied in a named population by a named route — never as guidance. ## Thymosin alpha-1 Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated polypeptide first isolated from calf thymus as part of "thymosin fraction 5," with Goldstein and colleagues purifying it and determining its complete sequence in 1977 [1]. It is highly acidic, carries no aromatic residues and no disulfide bonds, and is cleaved in the body from a 113-amino-acid precursor, prothymosin alpha [1]. The N-terminal acetyl group is essential for activity — the synthetic drug `thymalfasin` is sequence-identical [4]. This is the molecule the rest of the page is about; everything downstream traces back to this structure. ## Mechanism — the dendritic-cell switch The peptide's central action is on dendritic cells. Working through Toll-like receptors TLR9 and TLR2, it drives dendritic-cell maturation, IL-12 production, and antigen presentation, which matures T-cells and polarizes them toward Th1 immunity (IFN-γ, IL-2) [5]. A landmark study showed it activates dendritic-cell tryptophan catabolism through IDO — an effect that required TLR9 and type I interferon receptor signalling and produced IL-10 plus regulatory T-cells, establishing a tolerogenic frame around the Th1 priming [5]. In severe disease it expands cytotoxic CD8+ T-cells and reverses T-cell exhaustion, lowering PD-1 and Tim-3 [6], and it restores monocyte HLA-DR in immune paralysis [2]. The dual signature — lift the suppressed, restrain the inflamed — falls directly out of this mechanism. ## Thymosin alpha 1 peptide As a thymosin alpha 1 peptide drug, its pharmacology is well characterized. After subcutaneous injection in humans the serum half-life is roughly 2 hours, peak concentration (30-80 mcg/L) arrives within 1-2 hours, the volume of distribution (~30-40 L) matches extracellular-fluid distribution, and blood levels return toward baseline within 24 hours [8]. A mouse biodistribution study found a rapid serum rise within two minutes lasting about two hours, high uptake in thymus, spleen, and lungs, and rapid renal excretion as the major clearance route [10]. Formulation work has pushed toward sustained release: PLGA microspheres achieved roughly 90% cumulative release over a month in vitro and raised the CD4+/CD8+ ratio in immunosuppressed rats [11]. ## Ta1 peptide The Ta1 peptide abbreviation (Tα1) is the same molecule under its shorthand, and US clinical interest in it is not new — Goldstein and colleagues summarized the status of United States thymosin trials for immune and neuroendocrine modulation as far back as 1990 [14]. A pharmacy monograph later consolidated the dosing, pharmacokinetics, and safety reference for the development program [9]. The shorthand shows up constantly in research-use communities; it always means the 28-amino-acid immune peptide on this page, never a different compound. ## Thymalfasin Thymalfasin is the International Nonproprietary Name for the synthetic, sequence-identical form of Thymosin Alpha-1 used in essentially every modern trial [4]. The synthetic peptide is approved as a drug in roughly 35 countries — for chronic hepatitis B and as an immune adjuvant — and is usually well tolerated, with local injection-site irritation the most common adverse effect [4]. It is the generic name a reader will meet in the trial literature; the foreign brand name is not used on this site by design. ## Thymosin alpha 1 covid The thymosin alpha 1 covid record is genuinely mixed, and the honesty matters. In a retrospective review of 76 patients with severe COVID-19, treatment was associated with significantly reduced mortality (11.11% versus 30.00%) and reversed T-cell exhaustion, restoring T-cell numbers in patients with severe lymphocytopenia [6]. An in-vitro study added mechanism: in SARS-CoV-2-stimulated immune cells the peptide reduced TNF-α, IL-6, and IL-8 while raising IL-10 [13]. But a 2022 systematic review of roughly 5,300 patients found no statistically significant overall mortality benefit — so the cohort signals are not confirmed at the level of pooled, controlled evidence. ## The hepatitis record — the strongest signal Where Thymosin Alpha-1 looks most convincing is chronic viral hepatitis. A meta-analysis of eight trials (583 patients) comparing lamivudine plus the peptide against lamivudine alone found the combination significantly superior for hepatitis B e-antigen seroconversion (45.1% versus 15.2%) and virological response, and the peptide plus entecavir outperformed entecavir alone in cirrhotic patients [12]. This is the indication where four decades of international data are most consistent — and the reason thymalfasin carries marketing approval abroad. ## The sepsis story — and the null trial Sepsis is where the record turns cautionary. The earlier multicentre ETASS trial of 361 patients reported 28-day mortality of 26.0% with the peptide versus 35.0% in controls — an absolute reduction of about nine points that did not reach conventional significance [2]. The definitive test came in 2025: the phase-3, double-blind, placebo-controlled TESTS trial enrolled 1,106 adults across 22 centres and found no significant difference in 28-day mortality (23.4% versus 24.1%; hazard ratio 0.99, P=0.93) [3]. The largest, most rigorous sepsis trial to date was null — which tempers the earlier positive but lower-quality results and is the single most important caveat on this page. ## Thymosin alpha 1 vs thymosin beta 4 The thymosin alpha 1 vs thymosin beta 4 distinction is the one this site most insists on, because the two are constantly confused. They share a family name and almost nothing else. Thymosin Alpha-1 is a 28-amino-acid acetylated *immune modulator* that acts on dendritic cells and T-cells [1][5]. Thymosin beta-4 (sold and discussed as TB-500) is a different 43-amino-acid actin-binding peptide studied for tissue repair and motility — a different sequence, a different size, a different mechanism, and a different use. TB-500 is the one on the prohibited-substance lists; Thymosin Alpha-1 is not it. Two further neighbors round out the confusion: thymulin (FTS), a zinc-dependent nonapeptide, and thymopentin (TP-5), a pentapeptide — both distinct molecules, neither interchangeable with this one. The [Thymosin Alpha-1 references](/references) page lists the primary sources for each claim here. --- A standing record of what the thymus's quiet peptide has been measured to do — read from the literature, not whispered from a clinic, and nothing here is dispensed, prescribed, or sold.